Cartesian Therapeutics Income Statement (2015-2026) | RNAC

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
19.66M24.43M29.94M34.00M39.27M20.71M16.80M5.94M5.25M6.55M8.27M5.84M33.27M-0.76M1.10M0.30M-1.45M0.08M
Operating items
Research & Development (Quarter)
14.46M20.95M20.32M17.69M19.18M16.54M18.97M18.62M17.78M13.00M21.85M9.74M12.66M11.40M11.31M14.67M14.87M13.80M14.69M19.46M
Selling, General & Administrative (Quarter)
4.75M5.45M5.54M5.54M6.23M5.77M6.32M5.70M6.11M6.61M22.04M9.45M7.03M6.56M7.09M8.31M7.24M7.72M8.20M7.11M
Other Operating Expenses (Quarter)
0.71M7.58M56.70M
Operating Expenses (Quarter)
19.21M26.40M25.86M23.23M25.41M22.31M25.29M24.32M23.89M19.62M44.60M19.19M19.69M17.96M25.97M22.99M22.11M21.52M79.59M26.58M
Operating Income (Quarter)
0.45M-1.97M4.08M10.77M13.86M-1.60M-8.50M-18.38M-18.64M-13.06M-36.33M-13.35M13.76M-17.57M-26.73M-21.89M-21.81M-21.07M-78.64M-26.50M
EBIT (Quarter)
0.45M-1.97M4.08M10.77M13.86M-1.60M-8.50M-18.38M-18.64M-13.06M-36.33M-13.35M13.76M-17.57M-26.73M-21.89M-21.81M-21.07M-78.64M-26.50M
Non-operating items
Non Operating Investment Income (Quarter)
-149.60M-6.89M
Interest & Investment Income (Quarter)
0.01M0.01M0.01M0.01M0.21M0.71M1.14M1.33M1.39M1.30M0.94M1.16M1.20M2.57M2.45M2.02M1.75M1.55M1.27M1.03M
Other Non Operating Income (Quarter)
0.01M-0.50M0.50M0.03M0.00M0.17M0.26M0.02M0.25M-0.71M0.51M0.29M0.25M-0.44M-0.01M-2.00M-0.00M
Non Operating Income (Quarter)
0.01M0.01M0.15M0.00M0.17M0.26M0.24M0.25M-0.06M0.51M0.29M0.25M-34.29M-0.01M-2.00M-0.00M
Net income details
EBT (Quarter)
-0.25M-2.07M12.38M10.08M13.35M-8.21M5.61M-17.86M-18.00M-9.00M-196.66M-12.18M14.95M-15.00M-24.28M-19.87M-20.06M-19.52M-77.37M-25.47M
Tax Provisions (Quarter)
15.83M0.14M-0.32M-0.29M
Profit After Tax (Quarter)
4.57M-17.89M12.24M28.78M8.60M-7.89M5.89M-21.66M-11.39M-9.00M-177.66M-56.82M13.84M-24.18M-10.25M-17.71M15.89M-35.90M-92.58M-39.18M
Income from Continuing Operations (Quarter)
-0.25M-17.89M12.24M10.08M13.35M-7.89M5.89M-17.86M-18.00M-9.00M-196.66M-12.18M14.95M-15.00M-24.28M-19.87M-20.06M-19.52M-77.37M-25.47M
Consolidated Net Income (Quarter)
-0.25M-17.89M12.24M10.08M13.35M-7.89M5.89M-17.86M-18.00M-9.00M-196.66M-12.18M14.95M-15.00M-24.28M-19.87M-20.06M-19.52M-77.37M-25.47M
Income towards Parent Company (Quarter)
-0.25M-17.89M12.24M10.08M13.35M-7.89M5.89M-17.86M-18.00M-9.00M-196.66M-12.18M14.95M-15.00M-24.28M-19.87M-20.06M-19.52M-77.37M-25.47M
Preferred Dividend Payments (Quarter)
4.21M2.63M
Net Income towards Common Stockholders (Quarter)
-0.25M-17.89M12.24M10.08M13.35M-7.89M5.89M-17.86M-11.39M-9.00M-196.66M-12.18M9.63M-15.00M-24.28M-19.87M13.26M-19.52M-77.37M-25.47M
Additional items
EPS (Basic) (Quarter)
0.04-0.160.120.230.06-0.050.03-4.24-2.23-1.74-41.56-10.500.58-1.130.13-0.680.51-1.38-3.57-1.46
EPS (Weighted Average and Diluted) (Quarter)
0.00-0.160.120.080.06-0.05-0.05-4.24-2.23-1.74-41.56-10.500.54-1.130.12-0.680.50-1.38-3.57-1.46
Shares Outstanding (Weighted Average) (Quarter)
113.52M113.16M114.33M124.23M148.51M152.85M1.04M5.11M5.11M5.13M1.04M5.41M11.07M21.47M17.28M25.90M25.94M26.00M25.97M26.86M
Shares Outstanding (Diluted Average) (Quarter)
121.18M115.17M114.33M127.57M148.51M143.79M145.87M5.11M5.11M5.13M5.17M5.41M11.07M14.56M17.36M25.90M26.45M25.96M25.97M26.86M
EBITDA (Quarter)
4.58M-17.90M12.23M28.75M8.72M-7.94M5.87M-21.67M-11.41M-9.02M-177.64M-56.83M13.85M-24.20M-10.27M-17.68M15.90M-35.91M-92.56M-39.19M
Interest Expenses (Quarter)
0.71M0.71M0.71M0.71M0.71M0.80M0.81M0.81M0.75M1.27M
Shares Outstanding (Quarter)
115.08M115.44M123.62M124.38M152.71M153.03M5.10M5.11M5.11M5.16M5.40M5.52M17.82M23.90M25.77M25.94M26.00M26.00M26.01M28.54M
Tax Rate (Quarter)
-766.121.113.91-5.14